Just three of the drugs on the list of 10 products selected for Medicare price negotiation are not currently rebated at levels that exceed the minimum discounts established by the Inflation Reduction Act, which means they offer the best potential for savings, according to a recent analysis by drug pricing data and analytics firm SSR Health.
Imbruvica, Enbrel, Stelara Offer Best Chance Of Savings From Medicare Negotiation In First Round
The other seven drugs on the initial list for negotiation are already heavily rebated and CMS could choose not to go much lower than current net prices, SSR Health report points out.
